Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL clinical trials
3 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic use (Phase IV)
Arthritis interception with Guselkumab in subclinical psoriatic arthritis patients in clinical transition from skin to joint disease: a randomized clinical trial.
This study looks at whether a new medicine, Guselkumab, can help people with early signs of psoriatic arthritis (PsA) before it fully develops. It compares Guselkumab with another medicine, Ciclosporin, to see which is better at preventing joint pain and inflammation.
For: PSORIATIC ARTHRITIS PATIENTS IN CLINICAL TRANSITIONItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3b, Randomized, Double-blind, Parallel Group, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patients with Moderate-to-Severe Plaque-Type Psoriasis
This study is testing a new way to treat moderate to severe psoriasis. We want to see if combining the existing medicine guselkumab with other treatments works better. Doctors will compare different treatment plans to find the most effective and safest options for people living with psoriasis.
For: Moderate to Severe Plaque Type PsoriasisGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)
This study looks at two medicines, Stelara and Guselkumab, for young people with a type of arthritis called juvenile psoriatic arthritis. It checks how well they work, how safe they are, and how the body handles them.
For: Juvenile psoriatic arthritisFrance · Poland · Netherlands